Keryx Biopharmaceuticals


Analysts Weigh In On Keryx Biopharmaceuticals Following 2Q:15 Results

Keryx Biopharmaceuticals (NASDAQ:KERX) reported  second-quarter financial results yesterday and provided an update on its ongoing US launch of its dialysis drug, Auryxia. The Boston-based …

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results

Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results …

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer

Keryx Biopharmaceuticals (NASDAQ:KERX) announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately.

Analysts Weigh in on Keryx Biopharmaceuticals (KERX) as it Gains Positive Opinion for Fexeric in Europe

Health care analysts are weighing in today on the drug maker Keryx Biopharmaceuticals (NASDAQ:KERX), following the news that the Committee for Medicinal Products for Human Use in …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Receives CHMP Positive Opinion for Fexeric(R)

Keryx Biopharmaceuticals (NASDAQ:KERX) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion …

Here’s Why Cowen Downgraded Keryx Biopharmaceuticals to Market Perform

In a research report issued on today, Cowen analyst Boris Peaker downgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from an Outperfrom to a Market Perform …

Thursday Morning Insights: Keryx Biopharmaceuticals (KERX), SanDisk Corporation (SNDK), QUALCOMM, Inc. (QCOM), Cirrus Logic, Inc. (CRUS)

Keryx Biopharmaceuticals (NASDAQ:KERX) shares fell more than -5% in pre-market trading down to $9.06 after Boris Peaker at Cowen & Co.

Keryx Biopharmaceuticals (KERX)’s Auryxia Added to Two Medical Formularies; Analysts Weigh In

On Wednesday, Keryx Biopharmaceuticals (NASDAQ:KERX) made the announcement that two major insurance providers added Auryxia, a drug used to control serum phosphorous levels in patients with …

Maxim Weighs In On Keryx Biopharmaceuticals Following Additional Coverage By Two National Insurance

Maxim Group analyst Jason Kolbert weighed in today with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX) after the company announced that two national insurance providers have added …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D Formularies

Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, announced that two national insurance providers …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts